Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
LAMA + LABA

Umeclidinium with vilanterol

Brand names: Anoro Ellipta

Umeclidinium with vilanterol is a fixed-dose once-daily maintenance inhaler pairing a long-acting muscarinic antagonist (LAMA) with a long-acting beta-2 agonist (LABA) for COPD. It is taken regularly for symptom control rather than as a reliever.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Umeclidinium blocks muscarinic receptors to limit cholinergic bronchoconstriction and vilanterol activates beta-2 adrenoceptors to relax airway smooth muscle, giving complementary long-acting bronchodilatation.

Prescribing in practice

  • Avoid the umeclidinium component in angle-closure glaucoma and use cautiously in significant bladder-outflow obstruction or prostatic disease because of antimuscarinic effects.
  • Caution applies with the vilanterol LABA in cardiovascular disease, arrhythmias and hyperthyroidism, and hypokalaemia may be worsened by steroids and diuretics.
  • It is a maintenance treatment only, so a separate short-acting bronchodilator is required for acute breathlessness.

Monitoring

Monitor symptom control, exacerbation frequency, inhaler technique and antimuscarinic or cardiovascular adverse effects.

Counselling the patient

  • Take it once daily at the same time for prevention, not for sudden symptoms.
  • Report eye pain or visual halos, or difficulty passing urine, promptly.

Evidence & guidelines

This LAMA/LABA combination is supported by COPD trial evidence and NICE guidance favouring dual bronchodilation for persistent symptoms.

Reference: NICE NG115; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways